December 9, 2016 / 1:44 PM / 7 months ago

BRIEF-Synergy Pharma's bowel drug succeeds in first phase 3 trial

1 Min Read

Dec 9 (Reuters) - Synergy Pharmaceuticals Inc :

* Synergy Pharmaceuticals announces positive results in first phase 3 trial of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C)

* Synergy Pharmaceuticals Inc - preliminary analysis of data indicates that both plecanatide 3 mg and 6 mg doses met study's primary endpoint

* Synergy Pharmaceuticals -pending approval in CIC indication, co plans to file new drug application supplement with clinical data for plecanatide in IBS-C in q1 2017

* Synergy Pharmaceuticals Inc - four patients in trial (0.4%) experienced serious adverse events

* Synergy Pharma- common adverse event was diarrhea that was in 3.2% of patients in 3 mg,3.7% patients in 6 mg dose groups versus 1.3% placebo-treated patients

* Synergy Pharmaceuticals announces positive results in first phase 3 trial of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below